News
Market and company headlines
Key TakeawaysGlobe Life shares fell 8% after Piper Sandler downgraded the stock to Neutral from Overweight and cut its price target to $165 from $200. Piper Sandler says Globe Life is no longer a predictable safe haven, pointing to bigger medical claims, irregular Medicare supplement claims and softer 2027 guidance.

Evercore ISI Group analyst Thomas Gallagher maintains Globe Life (NYSE:GL) with a In-Line and lowers the price target from $176 to $174.

TD Cowen analyst Andrew Kligerman maintains Globe Life (NYSE:GL) with a Buy and lowers the price target from $225 to $215.

Globe Life’s third quarter saw solid revenue growth, yet the market responded negatively after adjusted earnings came in below analyst expectations. Management pointed to operational headwinds in its United American General Agency Division, most notably due to a process change at the Centers for Medicare & Medicaid Services (CMS) that led to elevated claims. Additionally, the Evri group health business experienced higher-than-expected severity in claims, contributing to lower underwriting margin
Globe Life stock barely flinched after Q3 2026 earnings, slipping about 0.7% to US$168.41 even as the insurer posted basic earnings per share of US$4.71 and net income of US$361.1m. Short-term traders see a quiet tape. Longer term investors see a different story, centred on a company with a trailing P/E of 10.9 that sits well below a peer average of 39.2 and a model valuation that suggests the shares trade at a steep discount. If you like Globe Life’s valuation profile and are looking for...

Piper Sandler analyst Paul Newsome downgrades Globe Life (NYSE:GL) from Overweight to Neutral and lowers the price target from $200 to $165.
Globe Life (NYSE:GL) reported third-quarter net income of $361 million, or $4.62 per share, down 2% from $4.73 per share a year earlier. Net operating income rose 1% to $379 million, or $4.84 per share, compared with $4.81 per share in the prior-year quarter. Co-Chief Executive Officer Frank Svobod

Premium revenue grew 7% despite health segment headwinds from CMS delays.

Shares of insurance holding company Globe Life (NYSE:GL) fell 3.4% in the morning session after the company reduced its full-year 2026 earnings outlook and posted a drop in third-quarter net income.

GL's Q3 2026 earnings miss estimates as weaker underwriting income and rising expenses offset higher premiums and investment income.

While the top- and bottom-line numbers for Globe Life (GL) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Globe Life (GL) delivered earnings and revenue surprises of -0.62% and -0.03%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Globe Life targets stronger premium growth in 2026, backed by rising investment income, AI adoption, agency expansion and substantial shareholder returns.

Get a deeper insight into the potential performance of Globe Life (GL) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Wells Fargo analyst Wesley Carmichael maintains Globe Life (NYSE:GL) with a Overweight and raises the price target from $190 to $191.

Globe Life is heading into earnings with strong market momentum and improving fundamentals, though caution lingers.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life insurance industry, including Globe Life (NYSE:GL) and its peers.

Globe Life Co CEOs Matt Darden + Frank Svoboda join Kristen Scholer on NYSE Live to discuss Company’s Texas Strategy

Globe Life’s 20.2% return over the past six months has outpaced the S&P 500 by 9.3%, and its stock price has climbed to $171.06 per share. This performance may have investors wondering how to approach the situation.

GL's health business gains momentum from strong premium growth, rate increases and expanding distribution, though medical inflation poses risks.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Despite Globe Life’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.


